{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166122687",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166122687",
  "name" : "CPIC Guideline for tegafur and DPYD",
  "groups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128878",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128878",
    "name" : "Deficient activity",
    "annotations" : [ {
      "id" : 1446441852,
      "text" : "Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.",
      "textHtml" : "<p>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446441867,
      "text" : "Homozygous for deficient activity alleles; DPD deficiency.",
      "textHtml" : "<p>Homozygous for deficient activity alleles; DPD deficiency.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446441884,
      "text" : "Select alternative drug.",
      "textHtml" : "<p>Select alternative drug.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "DPYD:*13/*13", "DPYD:*13/*2A", "DPYD:*13/rs67376798A", "DPYD:*2A/*2A", "DPYD:*2A/rs67376798A", "DPYD:rs67376798A/rs67376798A" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "src" : "guidelineStrength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128879",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128879",
    "name" : "Intermediate activity",
    "annotations" : [ {
      "id" : 1446441900,
      "text" : "Decreased DPD activity (leukocyte DPD activity at 30-70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.",
      "textHtml" : "<p>Decreased DPD activity (leukocyte DPD activity at 30-70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446441920,
      "text" : "Heterozyogous; intermediate DPD activity, at risk for toxicity with drug exposure.",
      "textHtml" : "<p>Heterozyogous; intermediate DPD activity, at risk for toxicity with drug exposure.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446441935,
      "text" : "Start with at least a 50% reduction in starting dose, followed by titration of dose based on toxicity (increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities) or pharmacokinetic test (if available).",
      "textHtml" : "<p>Start with at least a 50% reduction in starting dose, followed by titration of dose based on toxicity (increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities) or pharmacokinetic test (if available).</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "DPYD:*1/*13", "DPYD:*1/*2A", "DPYD:*1/rs67376798A", "DPYD:*13/*4", "DPYD:*13/*5", "DPYD:*13/*6", "DPYD:*13/*9A", "DPYD:*13/rs67376798T", "DPYD:*2A/*4", "DPYD:*2A/*5", "DPYD:*2A/*6", "DPYD:*2A/*9A", "DPYD:*2A/rs67376798T", "DPYD:*4/rs67376798A", "DPYD:*5/rs67376798A", "DPYD:*6/rs67376798A", "DPYD:*9A/rs67376798A", "DPYD:rs67376798A/rs67376798T" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501931",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501931,
      "src" : "guidelineStrength",
      "term" : "Moderate",
      "termId" : "guidelineStrength:981501931"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128880",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128880",
    "name" : "Normal activity",
    "annotations" : [ {
      "id" : 1446441946,
      "text" : "Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity.",
      "textHtml" : "<p>Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1446441976,
      "text" : "Homozygous for normal activity alleles; high DPD activity.",
      "textHtml" : "<p>Homozygous for normal activity alleles; high DPD activity.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1446441996,
      "text" : "Use label-recommended dosage and administration.",
      "textHtml" : "<p>Use label-recommended dosage and administration.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "DPYD:*1/*1", "DPYD:*1/*4", "DPYD:*1/*5", "DPYD:*1/*6", "DPYD:*1/*9A", "DPYD:*1/rs67376798T", "DPYD:*4/*4", "DPYD:*4/*5", "DPYD:*4/*6", "DPYD:*4/*9A", "DPYD:*4/rs67376798T", "DPYD:*5/*5", "DPYD:*5/*6", "DPYD:*5/*9A", "DPYD:*5/rs67376798T", "DPYD:*6/*6", "DPYD:*6/*9A", "DPYD:*6/rs67376798T", "DPYD:*9A/*9A", "DPYD:*9A/rs67376798T", "DPYD:rs67376798T/rs67376798T" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501931",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501931,
      "src" : "guidelineStrength",
      "term" : "Moderate",
      "termId" : "guidelineStrength:981501931"
    }
  } ],
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA452620",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA452620",
    "name" : "tegafur"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA145",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA145",
    "symbol" : "DPYD",
    "name" : "dihydropyrimidine dehydrogenase"
  } ],
  "source" : "CPIC",
  "summaryHtml" : "<p>The CPIC Dosing Guidelines for fluoropyrimidines (i.e. 5-fluorouracil, capecitabine or tegafur) recommends an alternative drug for patients who are homozygous for DPYD non-functional variants - *2A (<a href=\"/rsid/rs3918290\">rs3918290</a>), *13 (<a href=\"/rsid/rs55886062\">rs55886062</a>), and <a href=\"/rsid/rs67376798\">rs67376798</a> A (on the positive chromosomal strand) - as these patients are typically DPD deficient.  Consider a 50% reduction in starting dose for heterozygous patients (intermediate activity).</p>",
  "textHtml" : "<h3 id=\"May2014UpdateonPharmGKB\">May 2014 Update on PharmGKB</h3><ul><li> The CPIC authors recommend that the <em>DPYD*4</em>, <em>*5</em>, <em>*6</em> and <em>*9A</em> alleles be categorized as \"normal\" activity, in part based upon the recent publication <a href=\"/redirect.jsp?p=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F%3Fterm%3D24648345\" target=\"offsite\">Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity</a>. </li></ul><h3 id=\"December2013Publication\">December 2013 Publication</h3><p><em>Accepted article preview online August 2013; Advance online publication October 2013.</em></p><ul><li>Guidelines regarding the use of pharmacogenomic tests in dosing for fluoropyrimidines have been published in <em>Clinical Pharmacology and Therapeutics</em> by the Clinical Pharmacogenetics Implementation Consortium (<a href=\"/contributors/consortia/cpic_profile.jsp\">CPIC</a>).</li><li>These guidelines are applicable to:<ul><li>at the time of this writing, there are no data available on the possible role of DPYD*2A, *13, or <a href=\"/rsid/rs67376798\">rs67376798</a> in 5-fluorouracil toxicities in pediatric patient populations; however, there is no reason to suspect that DPYD variant alleles would affect 5-fluorouracil metabolism differently in children compared to adults.</li></ul></li><li>Excerpt from the fluoropyrimidine dosing guideline based on DPYD genotype:<ul><li>\"The strength of the dosing recommendations is based on the fact that some variants (DPYD*2A, *13, and <a href=\"/rsid/rs67376798\">rs67376798</a>) clearly affect DPD activity, and DPD activity is clearly related to 5-fluorouracil clearance, and 5-fluorouracil exposure is associated with its toxic effects. Therefore, reduction of fluoropyrimidine dosage in patients with these variants may prevent severe and possibly life-threatening toxicities. However, available evidence does not clearly indicate a degree of dose reduction needed to prevent fluoropyrimidine related toxicities...[Based on literature review (see full manuscript),] our recommendation is to start with at least a 50% reduction of the starting dose followed by an increase in dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy, a decrease in dose in patients who do not tolerate the starting dose to minimize toxicities or pharmacokinetic guided dose adjustments (if available). Patients who are homozygous for DPYD*2A, *13, or <a href=\"/rsid/rs67376798\">rs67376798</a> may demonstrate complete DPD deficiency and the use of 5-fluorouracil or capecitabine is not recommended in these patients.\" </li></ul></li><li>Download and read:<ul><li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Ffluoropyrimidines%2F2013%2F23988873.pdf\" target=\"offsite\">Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing</a></li><li><a href=\"/redirect.jsp?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Ffluoropyrimidines%2F2013%2F23988873-supplement.pdf\" target=\"offsite\">2013 supplement</a></li></ul></li></ul><h5 id=\"h5-1\"></h5><h3 id=\"Table1Recommendeddosingoffluoropyrimidinesbygenotypephenotype.\">Table 1: Recommended dosing of fluoropyrimidines by genotype/phenotype.</h3><p><em>Adapted from Tables 1 and 2 of the 2013 guideline manuscript.</em></p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th>Phenotype (genotype)</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Dosing recommendations</th><th>Classification of recommendations <sup>a</sup></th></tr><tr><td>Homozygous wild-type or normal, high DPD activity (two or more functional *1 alleles)</td><td>*1/*1</td><td>Normal DPD activity and \"normal\" risk for fluoropyrimidine toxicity</td><td>Use label-recommended dosage and administration</td><td>Moderate</td></tr><tr><td>Heterozygous or intermediate activity (~3-5% of patients), may have partial DPD deficiency, at risk for toxicity with drug exposure (one functional allele *1, plus one nonfunctional allele - *2A, *13 or rs67376798A <sup>c</sup>)</td><td>*1/*2A; *1/*13; *1/ rs67376798A <sup>c</sup>)</td><td>Decreased DPD activity (leukocyte DPD activity at 30% to 70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Start with at least a 50% reduction in starting dose followed by titration of dose based on toxicity <sup>b</sup> or pharmacokinetic test (if available)</td><td>Moderate</td></tr><tr><td>Homozygous variant, DPD deficiency (~0.2% of patients), at risk for toxicity with drug exposure (2 nonfunctional alleles - *2A, *13 or rs67376798A <sup>c</sup>)</td><td>*2A/*2A; *13/*13; rs67376798A <sup>c</sup> / rs67376798A <sup>c</sup></td><td>Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs</td><td>Select alternate drug</td><td>Strong</td></tr></table><p><sup>a</sup> Rating scheme described in 2013 supplement.<br/><sup>b</sup> Increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.<br/><sup>c</sup> Note that the rs67376798A allele refers to the allele on the positive chromosomal strand.  This is important because DPYD is on the minus chromosomal strand and <a href=\"/rsid/rs67376798\">rs67376798</a> is a T/A snp.  Therefore, the T allele on the gene confers the deficiency, while the complement on the positive chromosomal strand (A allele) is indicative of deficiency.</p>"
}